Nuvation Bio Inc. (NYSE:NUVB) Receives Average Rating of “Moderate Buy” from Brokerages

Nuvation Bio Inc. (NYSE:NUVB) has received an average rating of “Moderate Buy” from the eleven brokerages that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $12.50.

Several equities research analysts have recently commented on NUVB shares. Zacks Research cut shares of Nuvation Bio from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvation Bio in a research report on Tuesday, April 21st. Royal Bank Of Canada reiterated an “outperform” rating and set a $20.00 price target on shares of Nuvation Bio in a research report on Tuesday, May 5th. UBS Group lowered their price target on shares of Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating for the company in a research report on Tuesday, March 3rd. Finally, Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Nuvation Bio in a report on Tuesday, May 5th.

Nuvation Bio Stock Up 3.4%

Shares of NYSE:NUVB opened at $4.94 on Thursday. Nuvation Bio has a one year low of $1.57 and a one year high of $9.75. The company has a 50 day moving average of $4.63 and a 200-day moving average of $5.93. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.44 and a quick ratio of 7.24. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -11.49 and a beta of 1.52.

Nuvation Bio (NYSE:NUVB) last issued its quarterly earnings results on Monday, May 4th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.04. Nuvation Bio had a negative net margin of 102.06% and a negative return on equity of 44.10%. The company had revenue of $83.23 million during the quarter, compared to analysts’ expectations of $66.22 million. On average, sell-side analysts forecast that Nuvation Bio will post -0.64 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Dongfang Liu sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $5.02, for a total transaction of $251,000.00. Following the completion of the transaction, the insider owned 18,000 shares in the company, valued at approximately $90,360. The trade was a 73.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kerry Wentworth sold 200,000 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $4.52, for a total transaction of $904,000.00. Following the transaction, the insider owned 53,000 shares of the company’s stock, valued at approximately $239,560. This represents a 79.05% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 286,750 shares of company stock valued at $1,339,118. Corporate insiders own 30.11% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Parallel Advisors LLC lifted its stake in Nuvation Bio by 51.9% in the third quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock valued at $28,000 after buying an additional 2,597 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Nuvation Bio in the fourth quarter worth $71,000. KBC Group NV bought a new stake in shares of Nuvation Bio in the first quarter worth $37,000. Patriot Financial Group Insurance Agency LLC bought a new stake in shares of Nuvation Bio in the first quarter worth $43,000. Finally, Swiss Life Asset Management Ltd bought a new stake in shares of Nuvation Bio in the third quarter worth $39,000. Institutional investors own 61.67% of the company’s stock.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.